Nicotine replacement and behavioral therapy for smoking cessation in pregnancy

Am J Prev Med. 2007 Oct;33(4):297-305. doi: 10.1016/j.amepre.2007.05.006.

Abstract

Background: This study examines whether adding nicotine replacement therapy (NRT) to cognitive-behavioral therapy (CBT) for pregnant smokers increases rates of smoking cessation.

Methods: An open-label randomized trial (Baby Steps, n=181) of CBT-only versus CBT+NRT (choice of patch, gum, or lozenge; 1:2 randomization) was used. Data were collected from 2003 through 2005; analyses were conducted in 2006 and 2007. Outcomes were biochemically validated self-reported smoking status at 7 weeks post-randomization, 38 weeks gestation, and 3 months postpartum.

Results: Women in the CBT+NRT arm were almost three times more likely than women in the CBT-only arm to have biochemically validated cessation at both pregnancy time points (after 7 weeks: 24% vs 8%, p=0.02; at 38 weeks gestation: 18% vs 7%, p=0.04), but not at 3 months postpartum (20% vs 14%, p=0.55). Recruitment was suspended early by an Independent Data and Safety Monitoring Board when an interim analysis found a higher rate of negative birth outcomes in the CBT+NRT arm than in the CBT-only arm. In the final analysis, the difference between the arms in rate of negative birth outcomes was 0.09 (p=0.26), when adjusted for previous history of preterm birth.

Conclusions: The addition of NRT to CBT promoted smoking cessation in pregnant women. This effect did not persist postpartum. More data are needed to determine safety parameters and to confirm the efficacy of NRT use during pregnancy.

Trial registration: ClinicalTrials.gov NCT00224419.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Behavior Therapy*
  • Female
  • Humans
  • Nicotine / therapeutic use
  • Nicotinic Agonists / therapeutic use
  • North Carolina
  • Pregnancy
  • Smoking Cessation / methods
  • Smoking Cessation / psychology*
  • Tobacco Use Disorder / drug therapy*

Substances

  • Nicotinic Agonists
  • Nicotine

Associated data

  • ClinicalTrials.gov/NCT00224419